… Erlotinib is registered for treatment of all patients with advanced non-small-cell lung cancer
(NSCLC). However, its efficacy for treatment of patients whose tumours are EGFR wild-type—…

… and were EGFR positive, erlotinib prolongs survival (median erlotinib, 13.6 months and
placebo… 18 erlotinib patients and 12 placebo patients. There are too few EGFR-negative patients …

… to continue erlotinib treatment. In this review we present a practical approach for …
erlotinib-related cutaneous side effects in Japanese patients with advanced non-small cell lung …

… The importance of EGFR in tumor growth and progression has been demonstrated in …
efficacy outcomes in patients with non-small cell lung cancer (NSCLC). Erlotinib prolonged overall …

… vinorelbine in chemotherapy-naïve elderly patients with advanced non-small cell lung cancer)
has compared gefitinib with vinorelbine in unselected patients over 70 years old [Crino et …

… non-small-cell lung cancer (NSCLC). The OPTIMAL study compared efficacy and tolerability
of the TKI erlotinib versus standard chemotherapy in the first-line treatment of patients with …

… cases with a focus on sensitivity to erlotinib. The study included 13 patients with EGFR mutant
lung carcinomas, which after detailed … All patients were treated with erlotinib. Eight of 11 …

… peutic option for treatment of advanced squamous cell lung cancer patients. Erlotinib and
gefitinib had a similar efficacy in advanced squamous cell lung cancer. The frequency of EGFR …

… among patients with non-small-cell lung cancer (NSCLC); the prognosis for patients with …
all patients with NSCLC and 50% of patients eventually develop BM [3, 4]. The incidence of …

… Erlotinib, however, is currently approved for use as second-line or third-line therapy in
patients with non-small cell lung cancer (NSCLC) based on the landmark BR.21 trial which …